Harbor Capital Advisors, Inc. Bicycle Therapeutics PLC Transaction History

Harbor Capital Advisors, Inc.

$1.31 Billion
Q2 2024

A detailed history of Harbor Capital Advisors, Inc. transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Harbor Capital Advisors, Inc. holds 55,289 shares of BCYC stock, worth $1.25 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

55,289

Previous 43,480 27.16%

Holding current value

$1.25 Million

Previous $1.08 Million 3.32%

% of portfolio

0.09%

Previous 0.14%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 09, 2024	BUY	$20.02 - $24.69 $236,416 - $291,564	11,809 Added 27.16%	55,289 $1.12 Million
Q1 2024 May 13, 2024	BUY	$16.75 - $26.1 $281,266 - $438,271	16,792 Added 62.92%	43,480 $1.08 Million
Q4 2023 Jan 08, 2024	BUY	$13.29 - $22.2 $32,932 - $55,011	2,478 Added 10.24%	26,688 $482,000
Q3 2023 Oct 20, 2023	BUY	$19.9 - $26.25 $62,983 - $83,081	3,165 Added 15.04%	24,210 $486,000
Q2 2023 Jul 11, 2023	BUY	$18.95 - $28.67 $36,251 - $54,845	1,913 Added 10.0%	21,045 $537,000
Q1 2023 Apr 26, 2023	SELL	$20.02 - $31.37 $100,400 - $157,320	-5,015 Reduced 20.77%	19,132 $406,000
Q4 2022 Jan 20, 2023	SELL	$20.37 - $32.9 $438,362 - $708,008	-21,520 Reduced 47.12%	24,147 $0
Q3 2022 Oct 28, 2022	SELL	$17.49 - $28.44 $93,746 - $152,438	-5,360 Reduced 10.5%	45,667 $1.06 Million
Q2 2022 Jul 26, 2022	BUY	$12.95 - $46.99 $286,000 - $1.04 Million	22,085 Added 76.31%	51,027 $856,000
Q1 2022 Apr 28, 2022	SELL	$40.12 - $59.5 $226,998 - $336,651	-5,658 Reduced 16.35%	28,942 $1.27 Million
Q4 2021 Feb 04, 2022	BUY	$41.7 - $61.14 $1.44 Million - $2.12 Million	34,600 New	34,600 $2.11 Million

Others Institutions Holding BCYC

# of Institutions

111

Shares Held

40.7M

Call Options Held

3.4K

Put Options Held

12.4K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $673M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.

Account

Harbor Capital Advisors, Inc. Bicycle Therapeutics PLC Transaction History